Haug Nancy A, Kieschnick Dustin, Sottile James E, Babson Kimberly A, Vandrey Ryan, Bonn-Miller Marcel O
PGSP-Stanford Psy.D. Consortium, Palo Alto University, Palo Alto, California.
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.
Cannabis Cannabinoid Res. 2016 Dec 1;1(1):244-251. doi: 10.1089/can.2016.0024. eCollection 2016.
The proliferation of cannabis dispensaries within the United States has emerged from patient demand for the legalization of cannabis as an alternative treatment for a number of conditions and symptoms. Unfortunately, nothing is known about the practices of dispensary staff with respect to recommendation of cannabis strains/concentrations for specific patient ailments. To address this limitation, the present study assessed the training and practices of cannabis dispensary staff. Medical and nonmedical dispensary staff (=55) were recruited e-mail and social media to complete an online survey assessing their demographic characteristics, dispensary features, patient characteristics, formal training, and cannabis recommendation practices. Fifty-five percent of dispensary staff reported some formal training for their position, with 20% reporting medical/scientific training. A majority (94%) indicated that they provide specific cannabis advice to patients. In terms of strains, dispensary staff trended toward recommendations of Indica for anxiety, chronic pain, insomnia, nightmares, and Tourette's syndrome. They were more likely to recommend Indica and hybrid plants for post-traumatic stress disorder (PTSD)/trauma and muscle spasms. In contrast, staff were less likely to recommend Indica for depression; hybrid strains were most often recommended for amyotrophic lateral sclerosis (ALS). In terms of cannabinoid concentrations, dispensary staff were most likely to recommend a 1:1 ratio of delta-9-tetrahydrocannabinol (THC):cannabidiol (CBD) for patients suffering from anxiety, Crohn's disease, hepatitis C, and PTSD/trauma, while patients seeking appetite stimulation were most likely to be recommended THC. Staff recommended high CBD for arthritis and Alzheimer's disease and a high CBD or 1:1 ratio for ALS, epilepsy, and muscle spasms. Although many dispensary staff are making recommendations consistent with current evidence, some are recommending cannabis that has either not been shown effective for, or could exacerbate, a patient's condition. Findings underscore the importance of consistent, evidence-based, training of dispensary staff who provide specific recommendations for patient medical conditions.
美国大麻药房的激增源于患者对大麻合法化的需求,将其作为多种病症和症状的替代治疗方法。不幸的是,对于药房工作人员针对特定患者疾病推荐大麻品种/浓度的做法,我们一无所知。为解决这一局限性,本研究评估了大麻药房工作人员的培训情况和做法。通过电子邮件和社交媒体招募了医疗和非医疗药房工作人员(n = 55),以完成一项在线调查,评估他们的人口统计学特征、药房特点、患者特征、正规培训以及大麻推荐做法。55%的药房工作人员报告称接受过与其职位相关的一些正规培训,其中20%报告接受过医学/科学培训。大多数人(94%)表示他们会为患者提供具体的大麻建议。在品种方面,药房工作人员倾向于为焦虑、慢性疼痛、失眠、噩梦和妥瑞氏症推荐印度大麻。他们更有可能为创伤后应激障碍(PTSD)/创伤和肌肉痉挛推荐印度大麻和杂交植物。相比之下,工作人员为抑郁症推荐印度大麻的可能性较小;杂交品种最常被推荐用于肌萎缩侧索硬化症(ALS)。在大麻素浓度方面,药房工作人员最有可能为患有焦虑、克罗恩病、丙型肝炎和PTSD/创伤的患者推荐δ-9-四氢大麻酚(THC):大麻二酚(CBD)比例为1:1的产品,而寻求刺激食欲的患者最有可能被推荐使用THC。工作人员为关节炎和阿尔茨海默病推荐高CBD产品,为ALS、癫痫和肌肉痉挛推荐高CBD或1:1比例的产品。尽管许多药房工作人员的推荐与当前证据一致,但有些人推荐的大麻对患者病情要么未显示出有效性,要么可能会使其病情加重。研究结果强调了对为患者医疗状况提供具体建议的药房工作人员进行一致的、基于证据的培训的重要性。